Published in Arthritis Care Res (Hoboken) on April 01, 2013
Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ (2015) 1.52
A revised estimate of the burden of illness of gout. Curr Ther Res Clin Exp (2013) 1.23
[Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)]. Z Rheumatol (2016) 0.91
Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study. BMJ Open (2014) 0.89
Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. J Rheumatol (2014) 0.87
Management of Gout and Hyperuricemia in CKD. Am J Kidney Dis (2017) 0.82
Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis (2014) 0.82
Racial disparities in the risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States. Semin Arthritis Rheum (2016) 0.81
Inappropriate prescription of allopurinol and febuxostat and risk of adverse events in the elderly: results from the REPOSI registry. Eur J Clin Pharmacol (2014) 0.81
Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheumatol (2015) 0.80
Gout: An old disease in new perspective - A review. J Adv Res (2017) 0.78
Allopurinol hypersensitivity syndrome in patients with hematological malignancies: characteristics and clinical outcomes. Korean J Intern Med (2015) 0.76
Prevention of rheumatic diseases: strategies, caveats, and future directions. Rheum Dis Clin North Am (2014) 0.75
The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale. Contemp Clin Trials (2016) 0.75
The cost-effectiveness of HLA-b*5801 screening to guide initial urate-lowering therapy for gout in the United States. Semin Arthritis Rheum (2016) 0.75
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol (1992) 60.45
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med (1998) 32.43
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (2007) 20.57
Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol (2003) 11.24
Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med (1995) 7.21
Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol (2001) 7.04
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA (2008) 5.59
Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension (2001) 4.41
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A (2005) 3.82
Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol (2002) 3.37
The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol (1990) 3.32
Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) (2010) 2.94
Research Issues: Dually Eligible Medicare and Medicaid Beneficiaries, Challenges and Opportunities. Health Care Financ Rev (1998) 2.79
Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol (2007) 2.71
Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother (1993) 2.69
Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis (2005) 2.65
Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension (2002) 2.47
Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) (2011) 2.14
Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum (2009) 2.07
A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf (2010) 1.95
The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum (1986) 1.94
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics (2008) 1.92
Using a claims database to investigate drug-induced Stevens-Johnson syndrome. Stat Med (1991) 1.77
Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics (2009) 1.75
Quality of Medicaid and Medicare data obtained through Centers for Medicare and Medicaid Services (CMS). Med Care (2007) 1.66
Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol (2007) 1.64
Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol (2002) 1.64
Asymptomatic hyperuricemia: to treat or not to treat. Cleve Clin J Med (2002) 1.56
HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics (2008) 1.49
Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis (1981) 1.33
HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant (2011) 1.10
A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures. Arch Dermatol (1991) 1.07
HLA and allopurinol drug eruption. Dermatologica (1989) 0.99
Allopurinol associated hypersensitivity reactions: cutaneous and renal manifestations. Aust N Z J Med (1977) 0.88
A systematic review of validated methods for identifying erythema multiforme major/minor/not otherwise specified, Stevens-Johnson Syndrome, or toxic epidermal necrolysis using administrative and claims data. Pharmacoepidemiol Drug Saf (2012) 0.83
European Dermatology Forum: skin diseases in Europe. Skin diseases with a high public health impact: toxic epidermal necrolysis and Stevens-Johnson syndrome. Eur J Dermatol (2008) 0.80
Hyperuricemia and gout. J Fam Pract (1982) 0.77
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med (2003) 5.09
Design of a national distributed health data network. Ann Intern Med (2009) 4.09
Handling drop-out in longitudinal studies. Stat Med (2004) 3.87
Classification and regression tree analysis in public health: methodological review and comparison with logistic regression. Ann Behav Med (2003) 3.74
Clinical and organizational factors associated with feeding tube use among nursing home residents with advanced cognitive impairment. JAMA (2003) 3.66
Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology (2004) 3.57
Unintended effects of a computerized physician order entry nearly hard-stop alert to prevent a drug interaction: a randomized controlled trial. Arch Intern Med (2010) 3.31
The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol (2006) 3.30
Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med (2012) 3.08
One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med (2014) 3.07
Inter-rater reliability of nursing home quality indicators in the U.S. BMC Health Serv Res (2003) 2.83
The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf (2012) 2.70
Evidence of dysregulation of dendritic cells in primary HIV infection. Blood (2010) 2.39
Effects of childhood primary hypertension on carotid intima media thickness: a matched controlled study. Hypertension (2006) 2.33
Where people die: a multilevel approach to understanding influences on site of death in America. Med Care Res Rev (2007) 2.23
Prediction modeling using EHR data: challenges, strategies, and a comparison of machine learning approaches. Med Care (2010) 2.01
Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med (2008) 1.99
Mitochondrial signal transduction in accelerated wound and retinal healing by near-infrared light therapy. Mitochondrion (2004) 1.87
Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics (2011) 1.84
Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol (2008) 1.80
Validation of diagnostic codes for outpatient-originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data. Pharmacoepidemiol Drug Saf (2010) 1.78
Black/White differences in pressure ulcer incidence in nursing home residents. J Am Geriatr Soc (2004) 1.76
Cyclosporine for ocular inflammatory diseases. Ophthalmology (2010) 1.75
On the estimation and use of propensity scores in case-control and case-cohort studies. Am J Epidemiol (2007) 1.71
Clinical and experimental applications of NIR-LED photobiomodulation. Photomed Laser Surg (2006) 1.67
Quality of Medicaid and Medicare data obtained through Centers for Medicare and Medicaid Services (CMS). Med Care (2007) 1.66
Health care for older Americans with multiple chronic conditions: a research agenda. J Am Geriatr Soc (2007) 1.65
Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf (2011) 1.63
Bereaved family member perceptions of quality of end-of-life care in U.S. regions with high and low usage of intensive care unit care. J Am Geriatr Soc (2005) 1.62
Daily pain that was excruciating at some time in the previous week: prevalence, characteristics, and outcomes in nursing home residents. J Am Geriatr Soc (2004) 1.56
Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study. PLoS One (2011) 1.54
Location, location, location: geographic clustering of lower-extremity amputation among Medicare beneficiaries with diabetes. Diabetes Care (2011) 1.54
Identifying potential adverse effects using the web: a new approach to medical hypothesis generation. J Biomed Inform (2011) 1.52
Risk factors for umbilical venous catheter-associated thrombosis in very low birth weight infants. Pediatr Blood Cancer (2009) 1.50
GCAP1 rescues rod photoreceptor response in GCAP1/GCAP2 knockout mice. EMBO J (2002) 1.49
Pressure ulcers and the transition to long-term care. Adv Skin Wound Care (2003) 1.49
Use of feeding tubes in nursing home residents with severe cognitive impairment. JAMA (2002) 1.48
Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant (2009) 1.46
Represcription of penicillin after allergic-like events. J Allergy Clin Immunol (2004) 1.44
Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry (2012) 1.42
Government expenditures at the end of life for short- and long-stay nursing home residents: differences by hospice enrollment status. J Am Geriatr Soc (2004) 1.40
Snapshots: chromatin control of viral infection. Virology (2013) 1.39
Is improved survival a class effect of angiotensin-converting enzyme inhibitors? Ann Intern Med (2004) 1.35
Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. PLoS One (2011) 1.32
Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces Tat-independent HIV-1 expression but blunts cell activation. J Virol (2006) 1.29
Online discussion of drug side effects and discontinuation among breast cancer survivors. Pharmacoepidemiol Drug Saf (2013) 1.28
Newborn screening for severe combined immunodeficiency; the Wisconsin experience (2008-2011). J Clin Immunol (2011) 1.25
Medication safety in older adults: home-based practice patterns. J Am Geriatr Soc (2005) 1.24
Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol (2008) 1.23
Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database. Pharmacoepidemiol Drug Saf (2013) 1.23
Risk factors for pressure ulcers among elderly hip fracture patients. Wound Repair Regen (2003) 1.19
Noninvasive evaluation of liver metabolism by 2H and 13C NMR isotopomer analysis of human urine. Anal Biochem (2003) 1.18
Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection. Hepatology (2012) 1.16
The quality of the quality indicator of pain derived from the minimum data set. Health Serv Res (2005) 1.16
The changing risk profile of the American adolescent smoker: implications for prevention programs and tobacco interventions. J Adolesc Health (2006) 1.15
Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. J Allergy Clin Immunol (2004) 1.14
Minimally invasive approach provides at least equivalent results for surgical correction of mitral regurgitation: a propensity-matched comparison. J Thorac Cardiovasc Surg (2013) 1.13
Is there cross-reactivity between penicillins and cephalosporins? Am J Med (2006) 1.13
Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology (2007) 1.13
Cisapride and ventricular arrhythmia. Br J Clin Pharmacol (2008) 1.13
Type 2 diabetes mellitus and the risk of colorectal cancer. Clin Gastroenterol Hepatol (2005) 1.12
Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob Agents Chemother (2013) 1.12
Randomized clinical trial of a customized electronic alert requiring an affirmative response compared to a control group receiving a commercial passive CPOE alert: NSAID--warfarin co-prescribing as a test case. J Am Med Inform Assoc (2010) 1.12
Migraine prevalence, socioeconomic status, and social causation. Neurology (2013) 1.12
Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. Am J Med (2010) 1.11
Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf (2012) 1.11
Diagnostic codes for sudden cardiac death and ventricular arrhythmia functioned poorly to identify outpatient events in EPIC's General Practice Research Database. Pharmacoepidemiol Drug Saf (2008) 1.09
Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. Ann Rheum Dis (2012) 1.08
The association of health literacy with adherence and outcomes in moderate-severe asthma. J Allergy Clin Immunol (2013) 1.08
GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr (2014) 1.07
Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J Acquir Immune Defic Syndr (2014) 1.07
Diagnostic E-codes for commonly used, narrow therapeutic index medications poorly predict adverse drug events. J Clin Epidemiol (2008) 1.05
Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis. Value Health (2010) 1.05
Hospitalization costs associated with warfarin-related bleeding events among older community-dwelling adults. Pharmacoepidemiol Drug Saf (2010) 1.04
Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network. Pharmacoepidemiol Drug Saf (2014) 1.04
Natural supplements for H1N1 influenza: retrospective observational infodemiology study of information and search activity on the Internet. J Med Internet Res (2011) 1.03
Researchers and HIPAA. Epidemiology (2007) 1.01
Validity and comparison of two measures of days supply in Medicaid claims data. Pharmacoepidemiol Drug Saf (2008) 1.00
Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics (2003) 1.00
Chronic statin therapy and the risk of colorectal cancer. Pharmacoepidemiol Drug Saf (2008) 1.00
Multivariable confounding adjustment in distributed data networks without sharing of patient-level data. Pharmacoepidemiol Drug Saf (2013) 0.99
Chronic wound repair and healing in older adults: current status and future research. Wound Repair Regen (2015) 0.97
Ocular disease in patients with ANCA-positive vasculitis. J Ocul Biol Dis Infor (2009) 0.95
NASA light-emitting diodes for the prevention of oral mucositis in pediatric bone marrow transplant patients. J Clin Laser Med Surg (2002) 0.95
A review of covariate selection for non-experimental comparative effectiveness research. Pharmacoepidemiol Drug Saf (2013) 0.95
HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model. Retrovirology (2013) 0.93
Telemedicine reduces absence resulting from illness in urban child care: evaluation of an innovation. Pediatrics (2005) 0.92
Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum (2013) 0.92
Developing a distributed research network to conduct population-based studies and safety surveillance. AMIA Annu Symp Proc (2008) 0.92
Impact of cognitive function on assessments of nursing home residents' pain. Med Care (2005) 0.91
Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract (2013) 0.91
Antidiabetic action of bezafibrate in a large observational database. Diabetes Care (2009) 0.90
Promoting independence for wheelchair users: the role of home accommodations. Gerontologist (2006) 0.90
Response of pediatric uveitis to tumor necrosis factor-α inhibitors. J Rheumatol (2013) 0.90
Epidemiologic studies of adverse effects of anti-retroviral drugs: how well is statistical power reported. Pharmacoepidemiol Drug Saf (2005) 0.89